{"id":62385,"date":"2026-04-04T21:44:43","date_gmt":"2026-04-04T13:44:43","guid":{"rendered":"https:\/\/flcube.com\/?p=62385"},"modified":"2026-04-04T21:45:49","modified_gmt":"2026-04-04T13:45:49","slug":"staidson-pharma-announces-182m-private-placement-to-advance-innovative-biologics-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62385","title":{"rendered":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline"},"content":{"rendered":"\n<p><strong>Staidson (Beijing) Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300204:SHE\">SHE: 300204<\/a>) announced plans to raise up to <strong>RMB 1.253 billion<\/strong> (approximately <strong>USD 182 million<\/strong>) through a <strong>private placement<\/strong>, with <strong>RMB 883 million<\/strong> (USD 128 million) of net proceeds earmarked for the <strong>research and development of innovative biologics<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Staidson (Beijing) Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Stock Code<\/strong><\/td><td>SHE: 300204<\/td><\/tr><tr><td><strong>Total Raise<\/strong><\/td><td>RMB 1.253 billion (USD 182 million)<\/td><\/tr><tr><td><strong>Net Proceeds Allocation<\/strong><\/td><td>RMB 883 million (USD 128 million) for R&amp;D<\/td><\/tr><tr><td><strong>Use of Funds<\/strong><\/td><td>Development of highly innovative biologics<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Private placement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-portfolio-amp-development-status\">Pipeline Portfolio &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Class:<\/strong> Highly innovative biologics<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Inflammatory diseases, respiratory conditions, ophthalmology, and reproductive health<\/li>\n\n\n\n<li><strong>Innovation Strategy:<\/strong> Advancing multiple late-stage candidates with significant unmet medical need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-pipeline\">Clinical Development Pipeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Candidate<\/th><th>Indication<\/th><th>Current Phase<\/th><th>Next Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>BDB-001<\/strong><\/td><td>ANCA-associated vasculitis<\/td><td>Phase III<\/td><td>NDA submission upon completion<\/td><\/tr><tr><td><strong>STSA-1002<\/strong><\/td><td>Acute respiratory distress syndrome<\/td><td>Phase III<\/td><td>NDA submission upon completion<\/td><\/tr><tr><td><strong>BDB-001<\/strong><\/td><td>Moderate-to-severe hidradenitis suppurativa<\/td><td>Phase II completed<\/td><td>Phase III initiation<\/td><\/tr><tr><td><strong>STSP-0902<\/strong><\/td><td>Neurotrophic keratitis<\/td><td>Phase II<\/td><td>Phase II data readout<\/td><\/tr><tr><td><strong>STSP-0902<\/strong><\/td><td>Oligoasthenospermia<\/td><td>Phase Ib<\/td><td>Phase Ib data readout<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The company&#8217;s dual-track approach with two Phase III candidates positions Staidson for potential near-term commercial launches, while earlier-stage programs expand its long-term growth runway across diverse therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-outlook\">Strategic Rationale &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biologics Transition:<\/strong> The capital raise accelerates Staidson&#8217;s strategic pivot from traditional pharmaceutical manufacturing to innovation-driven biologics development<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> With two Phase III assets in inflammatory and respiratory indications, Staidson addresses significant market gaps in China&#8217;s healthcare landscape<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Successful development of these biologics would establish new revenue streams beyond the company&#8217;s existing product portfolio<\/li>\n\n\n\n<li><strong>Investment Timeline:<\/strong> Management expects the funded programs to reach key clinical milestones within 12-24 months, with potential regulatory submissions for Phase III candidates as early as 2027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Staidson&#8217;s financing plans, clinical development timelines, and strategic objectives. Actual results may differ materially due to risks including regulatory approvals, clinical trial outcomes, market conditions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8212\u6cf0\u795e\uff1a\u8212\u6cf0\u795e\uff08\u5317\u4eac\uff09\u751f\u7269\u5236\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f82025\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u8212\u6cf0\u795e\uff1a\u8212\u6cf0\u795e\uff08\u5317\u4eac\uff09\u751f\u7269\u5236\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f82025\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09.\"><\/object><a id=\"wp-block-file--media-9dc8b6fa-1e31-4e91-9896-f86977af9713\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8212\u6cf0\u795e\uff1a\u8212\u6cf0\u795e\uff08\u5317\u4eac\uff09\u751f\u7269\u5236\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f82025\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09.pdf\">\u8212\u6cf0\u795e\uff1a\u8212\u6cf0\u795e\uff08\u5317\u4eac\uff09\u751f\u7269\u5236\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f82025\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/\u8212\u6cf0\u795e\uff1a\u8212\u6cf0\u795e\uff08\u5317\u4eac\uff09\u751f\u7269\u5236\u836f\u80a1\u4efd\u6709\u9650\u516c\u53f82025\u5e74\u5ea6\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884c\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9dc8b6fa-1e31-4e91-9896-f86977af9713\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[],"class_list":["post-62385","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62385\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline\" \/>\n<meta property=\"og:description\" content=\"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62385\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T13:44:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T13:45:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline\",\"datePublished\":\"2026-04-04T13:44:43+00:00\",\"dateModified\":\"2026-04-04T13:45:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385\"},\"wordCount\":339,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62385#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62385\",\"name\":\"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T13:44:43+00:00\",\"dateModified\":\"2026-04-04T13:45:49+00:00\",\"description\":\"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62385\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62385#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62385","og_locale":"en_US","og_type":"article","og_title":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline","og_description":"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.","og_url":"https:\/\/flcube.com\/?p=62385","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T13:44:43+00:00","article_modified_time":"2026-04-04T13:45:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62385#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62385"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline","datePublished":"2026-04-04T13:44:43+00:00","dateModified":"2026-04-04T13:45:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62385"},"wordCount":339,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62385#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62385","url":"https:\/\/flcube.com\/?p=62385","name":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T13:44:43+00:00","dateModified":"2026-04-04T13:45:49+00:00","description":"Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253 billion (approximately USD 182 million) through a private placement, with RMB 883 million (USD 128 million) of net proceeds earmarked for the research and development of innovative biologics.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62385#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62385"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62385#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62385"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62385\/revisions"}],"predecessor-version":[{"id":62389,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62385\/revisions\/62389"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}